Skip to main content
Signal8

Helix BioPharma Corp. (HBPCF)

Sector: Biotechnology

Industry: Biotechnology

Helix BioPharma Corp. logo

Helix BioPharma Corp.

OTC:HBPCFHealthcare
CLOSED
Mkt Cap$130.61M
EV-
Float46.72M
O/S169.62M
VOL200 sh
$ Vol$248
Inst Own-
Net Cash/Sh-
EarningsDec 10 · in 3w
Dilution
Historical Data
DateOpenHighLowCloseVolume
Nov 16, 20261.711.710.77000.7700100
Nov 13, 20260.77000.77000.77000.7700100
Nov 12, 20260.77000.77000.77000.7700100
Nov 11, 20260.77000.77000.77000.7700100
Nov 10, 20260.77000.77000.77000.7700100
Nov 9, 20260.77000.77000.77000.7700100
Nov 6, 20260.77000.77000.77000.7700100
Nov 5, 20260.77000.77000.77000.7700100
Nov 4, 20260.77000.77000.77000.7700100
Nov 3, 20260.77000.77000.77000.7700100
Oct 30, 20260.77000.77000.77000.7700100
Oct 29, 20260.77000.77000.77000.7700100
Oct 28, 20260.77000.77000.77000.7700100
Oct 27, 20260.77000.77000.77000.7700100
Oct 26, 20260.77000.77000.77000.7700100
Oct 23, 20260.77000.77000.77000.7700100
Oct 21, 20260.77000.77000.77000.7700100
Oct 20, 20260.77000.77000.77000.7700100
Oct 19, 20260.77000.77000.77000.7700100
Oct 16, 20260.77000.77000.77000.7700100
Analyst Coverage
No analyst coverage for this companyNo ratings, price targets, or covering firms on file.
About

Helix BioPharma Corp. is a Canadian enterprise focused on immuno-oncology.

The company's research and development efforts include L-DOS47, a drug candidate aimed at treating non-small cell lung cancer, and V-DOS47, which is designed to interact with vascular epithelial growth factor receptor 2 (VEGFR2). Helix has established collaborative agreements to further its research. One such partnership with Moffitt Cancer Center involves studying L-DOS47's pharmacodynamics and exploring the advantages of co-administering it with immune checkpoint inhibitors. A separate collaboration with University Hospital Tuebingen focuses on evaluating L-DOS47's therapeutic impact on CEACAM6-positive cancer models, employing advanced preclinical metabolic imaging techniques.

The company's corporate headquarters are located in Toronto, Canada.

Key Metrics
Market Cap$130.61M
Enterprise Value--
P/E Ratio--
Est. Net Cash/Share--
Institutional Ownership--

based on 169.62M shares outstanding

SectorHealthcare
IndustryBiotechnology
ExchangeOTC
CountryCACA
IPO Date-
Shares Outstanding169.62M
Authorized Shares
Float46.72M
52-Week Range
Volume
Average Daily Volume--

30d Avg

--

60d Avg

200

90d Avg

200

Earnings
Dividend History
No dividend history available